204 completed, 18 unknown, 14 terminated, 6 withdrawn. 243 Phase 3, 15 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 243 | Completed 204, Unknown 18, Terminated 14, Withdrawn 6, Enrolling by invitation 1 |
| Phase 2 | 15 | Completed 10, Unknown 3, Terminated 1, Withdrawn 1 |
Follow Osteoporosis: new trials by email Literature Review of Osteoporosis trials Research Report on Osteoporosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Compare the Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of MAB-22 Versus Prolia® MAB-22, Prolia® - Osteoporosis | Phase 3 | Withdrawn | Xentria, Inc. | 2025-10-01 | 2025-05-11 | |
| Effectiveness of 3D-printed Patient-specific Resorbable Scaffolds for Maxillary Bone Regeneration PCL Scaffold, PTFE + Bio-Oss® - Bone Loss, Jaw, Edentulous | Phase 3 | Enrolling by invitation | Universidad Austral de Chile | 10 | 2024-07-01 | 2025-01-15 |
| EffCaMgCit to Prevent Mineral Metabolism and Renal Complications of Chronic PPI Therapy EffCaMgCit, Placebo - Osteoporosis, Hypomagnesemia | Phase 3 | Withdrawn | University of Texas Southwestern Medical Center | 2024-04-19 | 2026-06-30 | |
| Study to Evaluate the Efficacy and Safety of PBK_L2201 in Postmenopausal Women With Osteoporosis PBK_L2201, Placebo - Osteoporosis | Phase 3 | Unknown | Pharmbio Korea Co., Ltd. | 60 | 2024-02-01 | 2023-12-04 |
| Clinical Controlled Study on the Efficacy of Denosumab in Treating Osteoporosis in the Domestic Population and Its Impact on Sarcopenia-related Outcomes Denosumab Injection, Normal saline injection (1.0ml/ branch) - Sarcopenia, Osteoporosis | Phase 3 | Unknown | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 86 | 2024-02-01 | 2024-08-16 |
| Comparative Efficacy, Safety, PK, and Immunogenicity Study Denosumab - Osteoporosis, Postmenopausal | Phase 3 | Unknown | Luye Pharma Group Ltd. | 392 | 2023-04-05 | 2024-04-26 |
| Multicenter Study in Postmenopausal Women With Osteoporosis, ALVOBOND AVT03, Denosumab - Osteoporosis, Postmenopausal | Phase 3 | Completed | Alvotech Swiss AG | 532 | 2022-08-23 | 2025-05-29 |
| A Phase 3 Study to Compare Biosimilar Denosumab With Prolia® ENZ215, Prolia - Postmenopausal Osteoporosis | Phase 3 | Completed | Enzene Biosciences Ltd. | 504 | 2022-07-04 | 2026-02-10 |
| A Phase III Clinical Study of Minodronate Tablets in Postmenopausal Women With Osteoporosis Minodronate Tablets and Alendronate Sodium Tablets-matching placebo;Alendronate Sodium Tablets and Minodronate Tablets -matching placebo - Osteoporosis | Phase 3 | Unknown | Shandong New Time Pharmaceutical Co., LTD | 330 | 2022-05-31 | 2022-03-31 |
| Denosumab Biosimilar Injection in Post Menopausal Women With Osteoporosis Denosumab, Denosumab-Ref - Osteoporosis, Postmenopausal | Phase 3 | Unknown | Lambda Therapeutic Research Ltd. | 552 | 2021-11-11 | 2023-10-13 |
| A Study to Test the Efficacy, Safety and Tolerability of Romosozumab Treatment in Postmenopausal Chinese Women With Osteoporosis Romosozumab, Placebo - Osteoporosis | Phase 3 | Completed | UCB Biopharma SRL | 327 | 2021-10-21 | 2026-09-28 |
| Comparative Efficacy and Safety Study of RGB-14-P and Prolia® in Women With Postmenopausal Osteoporosis RGB-14-P, Prolia® - Postmenopausal Osteoporosis | Phase 3 | Completed | Gedeon Richter Plc. | 473 | 2021-09-21 | 2024-10-24 |
| A Study to Evaluate the Efficacy, Pharmacodynamics, Safety, and Immunogenicity of FKS518 in Postmenopausal Women With Osteoporosis FKS518, US-licensed Prolia (Amgen) - Postmenopausal Osteoporosis | Phase 3 | Completed | Fresenius Kabi SwissBioSim GmbH | 553 | 2021-06-16 | 2025-02-27 |
| Clinical Efficacy and Safety Comparative Study Between CMAB807 Injection and Prolia® . CMAB807 Injection, Prolia® - Postmenopausal Osteoporosis | Phase 3 | Completed | Shanghai Biomabs Pharmaceutical Co., Ltd. | 278 | 2021-03-31 | 2025-02-20 |
| A Study to Test if TVB-009P is Effective in Relieving Postmenopausal Osteoporosis TVB-009, Prolia® - Osteoporosis, Postmenopausal | Phase 3 | Completed | Teva Pharmaceuticals USA | 332 | 2021-03-22 | 2026-10-01 |
| A Study to Compare SB16 (Proposed Denosumab Biosimilar) to Prolia® in Postmenopausal Women With Osteoporosis SB16 (Proposed Denosumab Biosimilar), Prolia® (Denosumab) - Postmenopausal Osteoporosis | Phase 3 | Completed | Samsung Bioepis Co., Ltd. | 457 | 2020-11-26 | 2025-02-04 |
| Efficacy and Safety of MW031 in PMO Subjects MW031, Placebo - Osteoporosis, Postmenopausal | Phase 3 | Completed | Mabwell (Shanghai) Bioscience Co., Ltd. | 448 | 2019-12-27 | 2023-10-11 |
| Alendronate Versus Denosumab in Kidney Transplant Patients Denosumab 60 mg/ml [Prolia], Alendronate 70Mg Tab - Osteoporosis, Osteopenia, Renal Transplant Recipient | Phase 2 / Phase 3 | Completed | Ain Shams University | 90 | 2019-10-17 | 2021-11-12 |
| DPP4-Inhibitors and Bone Metabolism in Diabetes Sitagliptin 100 mg, Placebo Tablets - Osteoporosis, Bone Loss, Postmenopausal | Phase 3 | Completed | Azienda Policlinico Umberto I | 132 | 2019-09-24 | 2025-01-13 |
| Treating Idiopathic Inflammatory Myopathies Related Reduced Bone Mineral Density With Denosumab or Zoledronic Acid Denosumab, Zoledronic Acid - Idiopathic Inflammatory Myopathies, Osteoporosis, Osteopenia | Phase 3 | Unknown | Kwong Wah Hospital | 40 | 2019-08-15 | 2019-07-26 |
Showing 20 of 243. Sign in to see all of them.
Osteoporosis, Postmenopausal (74) · Bone Diseases, Metabolic (46) · Breast Neoplasms (13) · Fractures, Bone (12) · Prostatic Neoplasms (9) · Motor Activity (6) · Bone Diseases (5) · Osteoporotic Fractures (5) · Cardiovascular Diseases (4) · Hip Fractures (4) · Spinal Fractures (4) · Vitamin D Deficiency (4) · Back Pain (3) · Diabetes Mellitus (3)
Metabolic Diseases (243) · Nutritional and Metabolic Diseases (243) · Musculoskeletal Diseases (240) · Bone Diseases (238) · Bone Diseases, Metabolic (197) · Neoplasms (26) · Wounds and Injuries (26) · Neoplasms by Site (24) · Urogenital Diseases (17) · Pathological Conditions, Signs and Symptoms (16) · Genital Diseases (15) · Skin and Connective Tissue Diseases (15) · Skin Diseases (14) · Breast Diseases (13)
Denosumab (37) · Alendronate (36) · Zoledronic Acid (28) · Risedronic Acid (24) · Teriparatide (23) · Cholecalciferol (18) · Vitamin D (16) · Calcium (15) · Ibandronic Acid (10) · Calcium Carbonate (9) · Duration of Therapy (8) · romosozumab (7) · Estrogens, Conjugated (USP) (6) · Absorptiometry, Photon (5) · Raloxifene Hydrochloride (5)
Amgen (21) · Eli Lilly and Company (19) · Novartis Pharmaceuticals (14) · Organon and Co (12) · Merck Sharp & Dohme LLC (7) · Hoffmann-La Roche (6) · Novartis (5) · Radius Health, Inc. (5) · Alliance for Clinical Trials in Oncology (4) · Columbia University (4) · Sanofi (4) · Shire (4) · Warner Chilcott (4) · ETOP IBCSG Partners Foundation (3) · GlaxoSmithKline (3)
United States (96) · Canada (41) · Poland (35) · Italy (24) · Australia (23) · France (23) · Spain (23) · Czechia (22) · Germany (22) · Hungary (22) · Argentina (21) · Denmark (21) · Belgium (19) · United Kingdom (16) · Mexico (15)
B. Cathy Craven, MD, FRCPC (2) · Dawn Hershman, MD (2) · Elizabeth Shane, MD (2) · Francesco Squadrito, MD (2) · Khashayar Sakhaee, MD (2)
PMID 38979716, PMID 21037195, PMID 31776637, PMID 19362675, PMID 20533525, PMID 22152181, PMID 31411768, PMID 31674644, PMID 32658264, PMID 34231877, PMID 36588166, PMID 38573517, PMID 15647811, PMID 15968009, PMID 16467232, PMID 16467233, PMID 16467234, PMID 16481635, PMID 16481636, PMID 16609086, PMID 16684825, PMID 16880313, PMID 16973975, PMID 17244788, PMID 17277040, PMID 17339618, PMID 17341712, PMID 17371886, PMID 17405972, PMID 17476007, PMID 17502530, PMID 17556697, PMID 17577003, PMID 17582069, PMID 17878149, PMID 17904460, PMID 17925539, PMID 18003959, PMID 18035193, PMID 18235052, PMID 18299491, PMID 18319414, PMID 18381571, PMID 18489937, PMID 18502208, PMID 18625626, PMID 18663162, PMID 18689371, PMID 18697901, PMID 18703472
2005 (2), 2008 (2), 2009 (2), 2016 (2), 2018 (2), 2004 (1), 2017 (1), N01AR002245 (1), P50AR044855 (1), P60AR047782 (1), R01AA014678 (1), R01AG019147 (1), R01AG032440 (1), R01AR046124 (1), R01AR048932 (1)